Name | Number of supported studies | Average coverage | |
---|---|---|---|
regulatory T cell | 6 studies | 20% ± 3% |
Insufficient scRNA-seq data for expression of ZC3H12D at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 98% | 520.37 | 942 / 966 | 91% | 3.66 | 480 / 527 |
stomach | 83% | 79.50 | 298 / 359 | 90% | 3.90 | 258 / 286 |
lung | 99% | 250.25 | 575 / 578 | 67% | 2.02 | 769 / 1155 |
thymus | 93% | 148.97 | 607 / 653 | 65% | 1.47 | 395 / 605 |
esophagus | 86% | 86.35 | 1248 / 1445 | 69% | 3.23 | 127 / 183 |
kidney | 96% | 142.74 | 85 / 89 | 48% | 1.05 | 431 / 901 |
bladder | 90% | 88.95 | 19 / 21 | 44% | 1.44 | 220 / 504 |
uterus | 92% | 73.15 | 157 / 170 | 37% | 0.73 | 171 / 459 |
breast | 90% | 108.75 | 411 / 459 | 39% | 0.95 | 438 / 1118 |
brain | 94% | 96.45 | 2472 / 2642 | 34% | 0.65 | 237 / 705 |
skin | 81% | 104.48 | 1469 / 1809 | 35% | 1.04 | 166 / 472 |
prostate | 93% | 109.20 | 227 / 245 | 7% | 0.16 | 37 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 32.10 | 29 / 29 |
spleen | 100% | 1762.79 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 1123.07 | 911 / 929 | 0% | 0 | 0 / 0 |
adipose | 98% | 183.20 | 1179 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 94% | 106.22 | 242 / 258 | 2% | 0.05 | 5 / 230 |
liver | 71% | 49.36 | 161 / 226 | 13% | 0.28 | 52 / 406 |
pancreas | 35% | 21.08 | 115 / 328 | 48% | 1.29 | 86 / 178 |
ovary | 62% | 39.06 | 111 / 180 | 20% | 0.32 | 87 / 430 |
tonsil | 0% | 0 | 0 / 0 | 80% | 2.65 | 36 / 45 |
blood vessel | 64% | 80.88 | 859 / 1335 | 0% | 0 | 0 / 0 |
heart | 57% | 42.47 | 488 / 861 | 0% | 0 | 0 / 0 |
muscle | 21% | 10.48 | 169 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 0.06 | 3 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0061158 | Biological process | 3'-UTR-mediated mRNA destabilization |
GO_0000932 | Cellular component | P-body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0005634 | Cellular component | nucleus |
GO_0004521 | Molecular function | RNA endonuclease activity |
GO_0005515 | Molecular function | protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | ZC3H12D |
Protein name | Zinc finger CCCH-type containing 12D Probable ribonuclease ZC3H12D (EC 3.1.-.-) (MCP-induced protein 4) (Transformed follicular lymphoma) (Zinc finger CCCH domain-containing protein 12D) (p34) |
Synonyms | MCPIP4 C6orf95 TFL |
Description | FUNCTION: May regulate cell growth likely by suppressing RB1 phosphorylation . May function as RNase and regulate the levels of target RNA species (Potential). In association with ZC3H12A enhances the degradation of interleukin IL-6 mRNA level in activated macrophages . Serve as a tumor suppressor in certain leukemia cells . Overexpression inhibits the G1 to S phase progression through suppression of RB1 phosphorylation . . |
Accessions | ENST00000458251.1 H0Y4Y6 B7ZBA4 ENST00000409806.8 [A2A288-1] ENST00000409948.1 A2A288 |